Company

Watson Labs Teva

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

MAY 12, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Minocycline Hydrochloride (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval for minocycline hydrochloride labeling; records a regulatory action, not a clinical trial or efficacy finding.

Regulatory UpdateWatson Labs Teva Minocycline Hydrochloride

Reported

Approval status date2026-05-12

FormulationMINOCYCLINE HYDROCHLORIDE, CAPSULE, ORAL, 5…

MAR 30, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Glipizide (Manufacturing (CMC))

U.S. Food and Drug Administration

FDA supplemental approval for manufacturing changes to an established generic drug; does not contain clinical efficacy or safety data.

Regulatory UpdateGlipizide Watson Labs Teva

Reported

Approval date2026-03-30

Submission typeSupplement (SUPPL)

Submission classManufacturing (CMC)